GSK3B and neoplasm: NTR1 antagonist SR48692 and special GSK3β phosphorylation inhibitor TWS119 were used to block the transduction of NTS signaling and the activation of Wnt/β-catenin pathway in NTS-treated Hep3Bwt cells and to validate whether NTS induces tumor EMT by activating the canonical Wnt/β-catenin pathway.